ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO009

Design of Kidney-Targeted Nanoparticles for Delivery of Gene Therapies

Session Information

Category: Bioengineering

  • 400 Bioengineering

Authors

  • Roach, Arantxa, The City College of New York, New York, New York, United States
  • Vasylaki, Anastasiia, The City College of New York, New York, New York, United States
  • Ghosh, Pratyusha, The City College of New York, New York, New York, United States
  • Jaimes, Edgar A., Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Williams, Ryan, The City College of New York, New York, New York, United States
Background

Therapeutic gene and drug delivery to organ sites outside of the liver remains elusive with few strategies to do so for renal diseases. In prior studies, we found that polymeric mesoscale nanoparticles (MNPs) localize to the kidneys up to 26-fold greater than any other organ, specifically to the renal proximal tubular epithelium.

Methods

Here, we investigated the potential to adapt this MNP platform to specifically deliver various RNA-based gene therapies to the renal proximal tubules. We formulated MNPs loaded with either reporter or gene-specific siRNA, mRNA, or CRISPR gRNA/Cas9 that conformed to the 300-400 nm diameter size range which demonstrates tubular localization. We then conducted in vitro studies using renal proximal tubular epithelial cells, as well as in vivo studies with healthy mice, to confirm their function and renal-specific delivery.

Results

Our results demonstrated successful modification of polymeric MNPs such that they maintained kidney targeting while encapsulating RNA therapeutics. mCherry mRNA-loaded MNPs exhibit rapid and bright protein translation in vitro with no cytotoxicity. GFP-targeted CRISPR gRNA/Cas9 MNPs turned off expression of GFP in a stably-transfected cell line. In vivo, we found that kidney-targeted MNPs specifically target the kidneys and achieve gene-specific knockdown.

Conclusion

In ongoing studies, we are using this modified MNP design to deliver gene therapies that modulate inflammation and oxidative stress in salt-sensitive hypertension models of chronic kidney disease.

a) Images of mesoscale nanoparticles. b) Kidney-specific delivery of fluorescently-labeled nucleic acids. c) GFP expression in vitro (bottom) is deleted by delivery of GFP CRISPR gRNA-Cas9 d) Renal cell lines (top) express mCherry fluorescent protein upon addition of mRNA-loaded MNPs. e) MNPs reduce gene expression specifically in the kidneys. f) Knockdown persists for up to 10 days.

Funding

  • Other NIH Support